Latest Articles in ICRA Ratings

Indian Pharma To Grow By 6-8% In FY24, Aided By Price Hikes In NLEMs: ICRA

The agency stated that the IPM witnessed a YoY growth of 7.7 per cent in 9M FY2023 supported by a price growth of 6.8 per cent and growth of 2.3 per cent from new product introductions, while volumes declined by 1.2 per cent. ICRA predicts that price increases will remain the primary growth driver f

Read More

Indian Hospital Industry To Post Robust Performance In FY2023: Report

The agency said that improving payor mix, growth in surgery volumes, price revisions by companies to offset cost inflation and faster throughput in discharges are expected to aid healthy growth of 8 to 10 per cent in average revenue per occupied bed (ARPOB) for the sample set in FY2023

Read More